Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.77 |
| ▸ | ADRB1 | P08588 | 14/20 | 0.77 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD1 | P21728 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2004900 | 1.00 | ADRB2 (0.77) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL2758562 | 0.90 | ADRB2 (0.80) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL3299628 | 0.90 | ADRB2 (0.80) | ADRB2ADRB1DRD2DRD1DRD4 | |
| Abediterol SCHEMBL29350050 | 0.87 | ADRB2 (1.00) | ADRB2ADRB1CHRM3 | |
| SCHEMBL4890724 | 0.87 | ADRB2 (0.61) | ADRB2ADRB1DRD2DRD1DRD4 | |
| Abediterol SCHEMBL243662 | 0.87 | ADRB2 (1.00) | ADRB2ADRB1CHRM3 | |
| Abediterol SCHEMBL241483 | 0.87 | ADRB2 (1.00) | ADRB2ADRB1CHRM3 | |
| SCHEMBL508917 | 0.87 | ADRB2 (0.76) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL242081 | 0.86 | ADRB2 (0.57) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL2007626 | 0.86 | ADRB2 (0.57) | ADRB2ADRB1DRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2828242-B1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | ALMIRALL SA (ES) | 2017-10-04 | — | — | EP | disclosed |
| US-9346759-B2 | Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| US-9108918-B2 | Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate | ALMIRALL, S.A. (ES) | 2015-08-18 | — | — | US | disclosed |
| US-9108918-B2 | Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate | ALMIRALL, S.A. (ES) | 2015-08-18 | — | — | US | disclosed |
| US-20150057256-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2--1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYTLATE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL S.A. (ES) | 2015-02-26 | — | — | US | disclosed |
| US-20150011769-A1 | PROCESS FOR PREPARING 5-(2--1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | ALMIRALL, S.A. (ES) | 2015-01-08 | — | — | US | disclosed |
| US-20150011769-A1 | PROCESS FOR PREPARING 5-(2--1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | ALMIRALL, S.A. (ES) | 2015-01-08 | — | — | US | disclosed |
| US-8524908-B2 | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one | ALMIRALL, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-8524908-B2 | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one | ALMIRALL, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-8524908-B2 | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one | ALMIRALL, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20120004414-A1 | PROCESS FOR MANUFACTURING 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE | ALMIRALL, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
| US-20120004414-A1 | PROCESS FOR MANUFACTURING 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE | ALMIRALL, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
| US-20120004414-A1 | PROCESS FOR MANUFACTURING 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE | ALMIRALL, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
| US-20110251165-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. | 2011-10-13 | — | — | US | disclosed |
| US-20110251166-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | PUIG DURAN CARLOS | 2011-10-13 | — | — | US | disclosed |
| EP-1885684-B1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA-2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2011-07-13 | — | — | EP | disclosed |
| US-7964615-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2011-06-21 | — | — | US | disclosed |
| EP-2263998-A1 | Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the beta2 adrenergic receptor | Almirall S.A. (ES) | 2010-12-22 | — | — | EP | disclosed |
| EP-2228368-A1 | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one | Almirall, S.A. (ES) | 2010-09-15 | — | — | EP | disclosed |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251166-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRA2C, ADRB1 | ADRB2 1/4885ADRB1 3/4885DRD2 89/4885 |
| US-20150011769-A1 | PROCESS FOR PREPARING 5-(2--1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | UGT1A8, UGT1A1, UGT8 | ADRB2 411/4885ADRB1 493/4885DRD2 402/4885 |
| US-20120004414-A1 | PROCESS FOR MANUFACTURING 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE | HAX1, CYP4B1, CYP4X1 | ADRB2 751/4885ADRB1 945/4885DRD2 672/4885 |
| US-20110251165-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRA2C, ADRB3 | ADRB2 1/4885ADRB1 4/4885DRD2 88/4885 |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ADRB2, ADRA2C, ADRB1 | ADRB2 1/4885ADRB1 3/4885DRD2 72/4885 |
| US-20150057256-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2--1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYTLATE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ADRA2C, ADRB2, ADRA2A | ADRB2 2/4885ADRB1 5/4885DRD2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.